-
EP4709729
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4709729
| EP4709729 - PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 13.02.2026 Database last updated on 08.04.2026 | |
| Former | The international publication has been made Status updated on 23.11.2024 | ||
| Former | unknown Status updated on 05.06.2024 | Most recent event Tooltip | 14.03.2026 | New entry: Renewal fee paid | Applicant(s) | For all designated states Jazz Pharmaceuticals Ireland Ltd. Fifth Floor, Waterloo Exchange Waterloo Road 4 Dublin / IE | [2026/12] | Inventor(s) | 01 /
JACKSON, Paula Macclesfield, Cheshire Cheshire SK10 4TG / GB | 02 /
AYLOTT, Helen Elizabeth Macclesfield, Cheshire Cheshire SK10 4TG / GB | 03 /
JONES, Clifford D Macclesfield, Cheshire Cheshire SK10 4TG / GB | 04 /
BHAMRA, Inder Macclesfield, Cheshire Cheshire SK10 4TG / GB | 05 /
RYAN, James Macclesfield, Cheshire Cheshire SK10 4TG / GB | 06 /
LENG, Daniel J Macclesfield, Cheshire Cheshire SK10 4TG / GB | 07 /
HO, Kelvin Macclesfield, Cheshire Cheshire SK10 4TG / GB | [2026/12] | Representative(s) | Eisenführ Speiser Patentanwälte Rechtsanwälte PartGmbB Gollierstraße 4 80339 München / DE | [2026/12] | Application number, filing date | 24729082.8 | 11.05.2024 | [2026/12] | WO2024IB54597 | Priority number, date | GB20230007077 | 12.05.2023 Original published format: GB 202307077 | GB20230019678 | 20.12.2023 Original published format: GB 202319678 | [2026/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2024236452 | Date: | 21.11.2024 | Language: | EN | [2024/47] | Type: | A1 Application with search report | No.: | EP4709729 | Date: | 18.03.2026 | Language: | EN | The application published by WIPO in one of the EPO official languages on 21.11.2024 takes the place of the publication of the European patent application. | [2026/12] | Search report(s) | International search report - published on: | EP | 21.11.2024 | Classification | IPC: | C07D487/04, C07D519/00, A61K31/517, A61P35/00 | [2026/12] | CPC: |
C07D519/00 (EP,IL);
A61P35/00 (EP,IL,KR);
C07D487/04 (EP,IL,KR);
A61K31/519 (KR);
A61K31/551 (KR);
A61K31/553 (KR);
C07D471/08 (KR);
C07D487/08 (KR);
C07D491/048 (KR);
C07D491/107 (KR);
C07D495/04 (KR);
C07D498/08 (KR);
C07D498/10 (KR)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2026/12] | Extension states | BA | Not yet paid | Validation states | GE | Not yet paid | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | PYRAZOLO[4,3-F!CHINAZOLINDERIVATE ALS MODULATOREN DES G12D-MUTANTEN KRAS ZUR BEHANDLUNG VON KREBS | [2026/12] | English: | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | [2026/12] | French: | DÉRIVÉS DE PYRAZOLO[4,3-F]QUINAZOLINE EN TANT QUE MODULATEURS DE MUTANTS KRAS G12D UTILES POUR LE TRAITEMENT DU CANCER | [2026/12] | Entry into regional phase | 12.12.2025 | National basic fee paid | 12.12.2025 | Designation fee(s) paid | 12.12.2025 | Examination fee paid | Examination procedure | 12.12.2025 | Examination requested [2026/12] | 12.12.2025 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 13.03.2026 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X] WO2021063346 (SHANGHAI DE NOVO PHARMATECH CO LTD et al.) | [A] WO2022184178 (JACOBIO PHARMACEUTICALS CO LTD et al.) | [I] WO2022247760 (SHANGHAI KECHOW PHARMA INC et al.) | [E] WO2024123102 (SK BIOPHARMACEUTICALS CO LTD et al.) | by applicant | WO2021041671 | WO2022248885 | WO2022258974 | HOBBS ET AL., JOURNAL OF CELL SCIENCE, vol. 129, 2016, pages 1287 - 1292 | "The AACR Project GENIE Consortium", CANCER DISCOVERY, vol. 7, no. 8, 2017, pages 818 - 831 | HOFFMAN ET AL., CANCER DISCOVERY, vol. 12, 2022, pages 924 - 937 | STAHLWERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH | HALEBLIAN, J PHARM SCI, vol. 64, no. 8, August 1975 (1975-08-01), pages 1269 - 1288 | T.W. GREENE: "Protective Groups in Organic Synthesis, A.", 1981, WILEY- INTERSCIENCE PUBLICATION | P. J. KOCIENSKI: "Protecting groups", 1994, GEORG THIEME VERLAG |